Silica Magnetic Beads for Viral RNA and DNA Extraction

Silica Magnetic Beads for Viral RNA and DNA Extraction: Quick Answer

Silica magnetic beads are used to isolate viral RNA and DNA through a reversible bind–wash–elute process.

First, a lysis buffer disrupts the viral particle and releases its nucleic acid. Binding salts, and often alcohol, then create conditions that allow viral RNA or DNA to adsorb onto the silica-coated surface of magnetic beads.

An external magnet collects the beads while proteins, lipids, salts, transport-medium components and other contaminants are removed. After washing, the purified viral nucleic acid is released into water or a low-salt elution buffer.

The basic workflow is:

1. Prepare the sample;

2. Lyse the viral particle;

3. Add an internal extraction control where required;

4. Create suitable binding conditions;

5. Bind viral RNA or DNA to silica magnetic beads;

6. Collect the beads with a magnet;

7. Wash away contaminants;

8. Remove residual wash solution;

9. Elute the purified nucleic acid;

10. Use the eluate for PCR, RT-PCR, digital PCR or sequencing.

Silica-coated magnetic beads combine the nucleic acid-binding properties of silica with rapid magnetic separation. Commercial viral extraction systems use this format for both manual and automated purification, including low-target samples and high-throughput workflows.

What Is Viral Nucleic Acid Extraction?

Viral nucleic acid extraction is the process of releasing, separating and purifying viral RNA or DNA from a biological, food, veterinary or environmental sample.

The extracted nucleic acid may subsequently be used for:

• PCR;

• Reverse-transcription PCR;

• Quantitative PCR;

• Digital PCR;

• Genotyping;

• Viral load research;

• Sequencing;

• Metagenomic analysis;

• Molecular surveillance;

• Assay development.

Extraction is not the same as amplification.

Extraction prepares the sample by removing substances that can interfere with downstream molecular reactions.

Potential contaminants include:

• Proteins;

• Lipids;

• Detergents;

• Hemoglobin;

• Anticoagulants;

• Mucus;

• Salts;

• Calcium compounds;

• Food particles;

• Humic substances;

• Transport-medium additives;

• Nucleases.

A molecular assay may fail even when viral nucleic acid is present if the extraction workflow does not remove enough inhibitors.

Why Silica Magnetic Beads Are Used for Viral Testing

Silica magnetic beads are particularly useful for viral nucleic acid extraction because viral targets are frequently present at low concentrations and must be recovered from complex sample matrices.

The main advantages include:

• High surface area for nucleic acid adsorption;

• Compatibility with viral RNA and DNA;

• No centrifugation during magnetic separation;

• Small-volume elution;

• Adaptability to different sample volumes;

• Manual and automated operation;

• High-throughput processing;

• Integration with PCR and sequencing workflows.

Thermo Fisher reports use of magnetic-bead viral nucleic acid purification with tissues, blood, serum, plasma, milk, swabs, feces and dried-card samples. NEB provides a silica magnetic bead workflow designed for viral DNA and RNA purification in manual and automated formats.

Mobile solid-phase contact

Magnetic beads move through the sample instead of remaining fixed inside a column.

When the beads are properly dispersed, the silica surface can contact viral nucleic acid throughout the liquid volume.

Automation compatibility

The beads can be:

• Immobilized in a well while liquid is removed;

• Transferred between reagent wells with a magnetic rod;

• Processed in 24-, 48- or 96-well formats;

• Integrated into proprietary diagnostic cartridges.

Flexible elution

A small elution volume can increase the concentration of recovered viral RNA or DNA.

However, excessively small elution volumes may reduce total recovery or make complete bead resuspension difficult.

How Silica Magnetic Beads Capture Viral RNA and DNA

A silica surface contains silanol groups.

Under ordinary aqueous conditions, silica and nucleic acids are strongly hydrated and often carry negative charges. Suitable binding buffers change this chemical environment.

Binding conditions commonly involve:

• Chaotropic salts;

• High ionic strength;

• Alcohol;

• Controlled pH;

• Reduced water activity.

These conditions reduce hydration and electrostatic repulsion, allowing nucleic acids to adsorb reversibly onto the silica surface.

Cytiva describes silica-coated magnetic beads as using chaotropic salt chemistry to promote reversible nucleic acid binding. Contaminants can then be washed away before the nucleic acid is released by changing the buffer conditions.

The magnetic core does not chemically bind the viral nucleic acid.

Its role is to make the silica solid phase easy to:

• Collect;

• Wash;

• Transfer;

• Resuspend;

• Automate.

Viral RNA Extraction vs Viral DNA Extraction

Silica magnetic beads can recover both viral RNA and viral DNA, but the workflows require different controls.

Viral RNA extraction

Viral RNA workflows should prioritize:

• Rapid sample stabilization;

• RNase-free handling;

• Effective nuclease inactivation;

• Efficient low-copy recovery;

• Minimal processing delay;

• RT-PCR inhibitor removal.

Viral DNA extraction

Viral DNA workflows should prioritize:

• Complete viral particle lysis;

• Efficient DNA recovery;

• Removal of proteins and inhibitors;

• Compatibility with the required fragment length;

• Low cross-contamination.

Total viral nucleic acid extraction

Many molecular diagnostic workflows use total nucleic acid extraction to recover viral RNA and DNA in the same procedure.

This can simplify multiplex assays, but the method must be validated separately for:

• RNA viruses;

• DNA viruses;

• Enveloped viruses;

• Non-enveloped viruses;

• Different target concentrations;

• Different sample types.

A high recovery result for one virus does not automatically demonstrate equivalent recovery for another.

Viral Lysis, Pathogen Inactivation and Biosafety Are Not the Same

Viral lysis releases nucleic acid from the viral particle.

Pathogen inactivation means that the sample no longer contains infectious virus under the validated test conditions.

These concepts should not be treated as interchangeable.

A lysis buffer may contain:

• Chaotropic salts;

• Detergents;

• Protein-denaturing agents;

• Reducing agents;

• Proteinase K.

Such reagents may disrupt viral envelopes, capsids and proteins. However, inactivation performance depends on:

• The virus;

• Viral concentration;

• Sample matrix;

• Reagent concentration;

• Sample-to-buffer ratio;

• Contact time;

• Temperature.

A generic nucleic acid extraction protocol should not be assumed to provide complete pathogen inactivation unless this has been specifically validated.

Laboratories should follow their institutional biosafety procedures and applicable requirements for handling potentially infectious samples.

Complete Viral Nucleic Acid Extraction Workflow

Step 1: Collect and Prepare the Sample

Record:

• Sample type;

• Collection device;

• Transport medium;

• Input volume;

• Storage time;

• Storage temperature;

• Freeze–thaw history;

• Visible debris or clots.

Sample preparation may include:

• Mixing;

• Centrifugation;

• Filtration;

• Homogenization;

• Dilution;

• Swab elution;

• Proteinase K pretreatment.

Promega notes that plasma, serum and saliva can be difficult to automate because of viscosity, clots, debris and variable pipetting behavior. Fecal samples typically require homogenization and debris management because they contain high biomass and amplification inhibitors.

Step 2: Lyse Viral Particles

Add an appropriate lysis buffer and mix thoroughly.

The lysis step should:

• Disrupt the viral envelope or capsid;

• Release RNA or DNA;

• Denature proteins;

• Reduce nuclease activity;

• Prepare the sample for binding.

Proteinase K may improve extraction from protein-rich matrices by digesting proteins and supporting viral particle disruption. Promega specifically discusses its usefulness with saliva, serum and other high-protein samples.

Incomplete lysis may produce:

• Low recovery;

• Variable Ct values;

• Poor precision near the detection limit;

• False-negative results in downstream testing.

Step 3: Add the Internal Extraction Control

An internal extraction control is a known nucleic acid target added to the sample or lysis mixture.

It can help identify:

• Extraction failure;

• Nucleic acid loss;

• PCR inhibition;

• Liquid-handling errors;

• Instrument problems.

The control should be added at a stage that allows it to pass through the relevant extraction steps.

Adding it only after extraction checks amplification but does not evaluate extraction recovery.

The internal control should not be so concentrated that it competes significantly with a low-copy viral target or masks extraction variation.

Step 4: Create the Binding Conditions

Add the binding buffer and alcohol where required by the chemistry.

Important variables include:

• Chaotropic salt concentration;

• Alcohol concentration;

• pH;

• Sample-to-buffer ratio;

• Total reaction volume;

• Bead dose.

Insufficient binding conditions can leave viral RNA or DNA in the supernatant.

Excessive salt or alcohol can increase downstream inhibition if washing is inadequate.

Step 5: Bind Viral RNA or DNA

Fully resuspend the silica magnetic beads before dispensing.

Add the required bead dose and mix the sample throughout the binding period.

Proper mixing is particularly important for:

• Plasma;

• Serum;

• Saliva;

• Mucus-containing swabs;

• Tissue lysates;

• Fecal suspensions.

Promega identifies mixing as one of the most important factors in automated viral nucleic acid extraction because it affects lysis, binding, washing and elution.

Step 6: Magnetically Separate the Beads

Apply the magnetic field and wait until the beads are sufficiently collected.

Collection time depends on:

• Particle size;

• Magnetic content;

• Sample viscosity;

• Liquid volume;

• Magnet strength;

• Vessel geometry.

Remove the supernatant without disturbing the bead pellet or ring.

Premature aspiration can remove beads together with the bound viral nucleic acid.

Step 7: Wash Away Proteins and PCR Inhibitors

Add the wash buffer and completely redisperse the beads where required.

Wash steps should remove:

• Proteins;

• Chaotropic salts;

• Detergents;

• Lipids;

• Hemoglobin;

• Transport-medium additives;

• PCR inhibitors.

A second wash formulation may be used to remove residual salts and prepare the beads for elution.

If the beads remain clumped during washing, contaminants can remain trapped within the pellet.

Step 8: Remove Residual Alcohol

After the final wash, remove residual wash liquid carefully.

Residual ethanol or isopropanol may inhibit:

• Reverse transcription;

• PCR;

• qPCR;

• Digital PCR;

• Library preparation.

The beads may require a controlled drying period.

Do not over-dry the particles, because an excessively dry and compact bead pellet may be difficult to resuspend and elute.

Step 9: Elute the Viral Nucleic Acid

Add:

• Nuclease-free water;

• Tris-based buffer;

• Another validated low-salt elution buffer.

Mix and incubate under validated conditions.

The nucleic acid detaches as the silica surface and target become rehydrated.

After final magnetic collection, transfer the eluate without carrying beads into the downstream assay.

What Each Reagent Does

Why Viral Nucleic Acid Extraction Is Challenging

Viral extraction differs from many genomic DNA workflows because the target may be present at only a few copies within a much larger sample background.

Major challenges include:

• Low viral concentration;

• Small sample input;

• Variable viral load;

• Short or fragile RNA;

• High host nucleic acid background;

• Sample viscosity;

• Protein-rich matrices;

• PCR inhibitors;

• Transport-medium variability;

• Viral particles with different structural stability.

Extraction performance near the assay’s detection limit is particularly important.

A method may perform well with high-positive samples but show unacceptable variation at low target concentrations.

Selecting Magnetic Beads for Low-Copy Viral Targets

For low-copy viral RNA or DNA, prioritize:

• High accessible silica surface area;

• Reliable low-input binding;

• Controlled nonspecific loss;

• Good redispersibility;

• Fast but complete magnetic collection;

• Low bead carryover;

• Efficient small-volume elution;

• Lot-to-lot consistency.

NEB describes submicron silica-coated magnetic beads as offering high surface area and abundant binding sites for low-target viral nucleic acid capture. Cytiva also positions silica-coated beads for applications involving small or trace nucleic acid quantities.

Smaller particles are not automatically better.

Very small beads may:

• Collect more slowly;

• Be more easily aspirated;

• Increase bead carryover;

• Require stronger magnets.

The selected size must balance surface area with separation performance.

How Carrier RNA Affects Viral Nucleic Acid Recovery

Carrier RNA may be added to some low-input viral extraction workflows.

Potential functions include:

• Improving recovery of small quantities of target nucleic acid;

• Reducing irreversible loss on vessel or solid-phase surfaces;

• Supporting more consistent binding;

• Acting as a co-precipitating or co-binding material.

QIAGEN notes that an appropriate carrier nucleic acid can improve the recovery of small nucleic acid quantities in silica-based purification.

Carrier RNA is not suitable for every workflow.

Potential disadvantages include:

• Increased total RNA background;

• Interference with certain quantification methods;

• Reduced suitability for untargeted RNA sequencing;

• Competition with target molecules under limited-capacity conditions.

Its use should be validated with the intended downstream assay.

Sample-Specific Extraction Considerations

Plasma and Serum

Plasma and serum are common matrices for circulating viral nucleic acid.

Challenges include:

• Low target concentration;

• High protein concentration;

• Viscosity;

• Fibrin or clot material;

• Anticoagulants;

• Variable sample quality.

Recommended development priorities include:

• Sample clarification where necessary;

• Accurate low-volume pipetting;

• Efficient proteinase K treatment;

• High low-copy recovery;

• Small-volume elution;

• Internal-control monitoring.

Thermo Fisher reports magnetic-bead viral RNA and DNA isolation from serum and plasma, while Promega highlights viscosity and debris as major automation considerations.

Respiratory and Nasopharyngeal Swabs

Respiratory swabs may contain:

• Mucus;

• Epithelial cells;

• Transport-medium additives;

• Variable sample volume;

• Low viral concentration.

Important variables include:

• Swab release efficiency;

• Transport-medium compatibility;

• Mucus reduction;

• Internal-control recovery;

• Cross-contamination prevention.

The workflow should be tested with all collection devices and transport media expected in routine use.

Saliva

Saliva can be highly variable in:

• Viscosity;

• pH;

• Food-particle content;

• Protein concentration;

• Salt composition.

Promega recommends considering proteinase K, sample clarification, dilution and appropriate liquid-handling settings for saliva workflows.

The method should be challenged with multiple donor samples rather than a single pooled matrix.

Whole Blood

Whole blood contains:

• Host cells;

• Hemoglobin;

• Plasma proteins;

• Anticoagulants;

• Large quantities of host DNA and RNA.

The extraction system should be evaluated for:

• Heme removal;

• Protein removal;

• Host-background effects;

• Magnetic collection in viscous lysate;

• Viral recovery near the detection limit.

Cell Culture Supernatant

Cell culture supernatant may be relatively simple, but it can still contain:

• Cellular debris;

• Serum proteins;

• Host nucleic acids;

• Media components;

• Low viral concentration.

A clarification step may improve consistency when cells or debris are present.

QIAGEN lists cell-culture supernatants among sample types used for viral RNA purification.

Tissue Samples

Tissues require:

• Homogenization;

• Protein digestion;

• Debris control;

• Sample-mass standardization.

The tissue-processing method can influence viral recovery more strongly than the magnetic bead dose.

Thermo Fisher has reported magnetic-bead viral RNA/DNA purification from multiple animal tissues and tissue homogenates.

Fecal Samples

Fecal material contains:

• High biomass;

• Complex proteins;

• Lipids;

• Polysaccharides;

• Bile components;

• Humic-like inhibitors.

Promega advises controlling sample mass and concentration because excessive fecal input can reduce pipetting consistency and increase inhibitor carryover. Thorough homogenization and wash resuspension are critical.

A higher sample mass does not necessarily improve detectable viral recovery.

Milk and Food Samples

Milk contains:

• Fat;

• Casein;

• Other proteins;

• Calcium;

• Microorganisms.

Food matrices vary widely in fat, protein, polysaccharide and pigment content.

NEB provides application material for magnetic viral nucleic acid purification from milk, while Thermo Fisher reports viral RNA/DNA extraction from milk among its tested sample types.

Sample-specific pretreatment is generally required.

Wastewater and Environmental Samples

Environmental viral targets may be:

• Highly diluted;

• Degraded;

• Bound to solids;

• Mixed with humic substances;

• Present with many other microorganisms.

These workflows may require:

• Concentration before extraction;

• Removal of suspended solids;

• Inhibitor-removal chemistry;

• Process controls added before concentration and extraction.

The method should separately evaluate concentration efficiency and magnetic-bead extraction efficiency.

Dried Blood and FTA Cards

Dried cards can support transport and storage of nucleic acid-containing samples.

Extraction may require:

• Punching or cutting a defined area;

• Controlled soaking or elution;

• Removal of card-derived inhibitors;

• Standardization of sample area.

Thermo Fisher reports viral RNA isolation from blood and oral swabs stored on FTA cards using magnetic-bead workflows.

Viral Transport Media and Collection Buffer Compatibility

Transport media may contain:

• Salts;

• Proteins;

• Antibiotics;

• Stabilizers;

• Inactivating chemicals;

• Detergents;

• Preservatives.

These components may alter:

• Lysis;

• Silica binding;

• Bead aggregation;

• Magnetic separation;

• PCR inhibition.

Compatibility should be tested using actual commercial transport media, not only water or a simple laboratory buffer.

Evaluate:

• Negative matrices;

• Low-positive samples;

• High-positive samples;

• Multiple lots;

• Stored and fresh samples;

• Different sample-to-medium ratios.

Total Nucleic Acid Extraction vs RNA-Only or DNA-Only Extraction

Total nucleic acid extraction

Total nucleic acid workflows recover both viral RNA and DNA.

Advantages include:

• One procedure for multiple pathogen types;

• Simplified multiplex assay development;

• Reduced need for separate extraction kits.

Potential disadvantages include:

• Higher background;

• Competition for bead capacity;

• More complex analytical validation.

RNA-focused extraction

RNA-focused methods may include:

• Strong RNase inactivation;

• DNase treatment;

• Conditions designed to preserve short and fragile RNA.

DNA-focused extraction

DNA-focused methods may include:

• RNase treatment;

• Conditions optimized for DNA recovery and purity;

• Different elution and storage requirements.

The method should be selected according to the molecular test, not only the virus classification.

Host Nucleic Acid Background and Target Enrichment

Clinical and biological samples may contain much more host nucleic acid than viral nucleic acid.

For targeted PCR, host background may be acceptable if it does not inhibit the assay.

For metagenomic or untargeted sequencing, high host DNA or RNA can reduce the proportion of viral reads.

Potential strategies include:

• Host-cell removal before lysis;

• Selective nuclease treatment;

• Viral particle enrichment;

• Sequence-specific capture;

• Host depletion after extraction.

These strategies require separate validation because they may also reduce viral recovery.

Standard silica magnetic beads are not sequence-specific. They bind nucleic acids according to buffer conditions rather than viral sequence.

Manual vs Automated Viral Nucleic Acid Extraction

A robust manual method should generally be established before automation.

The manual process provides a benchmark for determining whether poor automated recovery is caused by:

• Chemistry;

• Mixing;

• Magnetic collection;

• Liquid handling;

• Instrument programming.

Promega recommends retaining a manual control during automated viral extraction development.

Magnetic Rod Systems vs Liquid-Handling Workstations

Magnetic rod systems

A magnetic rod collects the beads and moves them between wells containing binding, wash and elution reagents.

Advantages include:

• Limited lysate aspiration;

• Efficient bead transfer;

• Reduced tip-clogging risk;

• Suitability for high-biomass samples.

Liquid-handling workstations

A liquid handler keeps the beads in the plate and transfers the liquids.

Advantages include:

• Flexible reagent volumes;

• Open protocols;

• Integration with PCR setup;

• Compatibility with multiple plate formats.

Liquid handlers require careful control of:

• Pipetting speed;

• Tip bore;

• Aspiration height;

• Magnet geometry;

• Sample viscosity.

How to Optimize Binding, Washing and Elution

Binding optimization

Evaluate:

• Bead amount;

• Sample-to-binding-buffer ratio;

• Alcohol concentration;

• Binding time;

• Mixing intensity;

• Temperature.

Test the discarded binding supernatant to determine whether target nucleic acid failed to bind.

Washing optimization

Evaluate:

• Wash-buffer composition;

• Wash volume;

• Number of washes;

• Bead redispersion;

• Residual inhibitors.

An extra wash may improve purity but can also increase bead and target loss.

Elution optimization

Evaluate:

• Elution volume;

• pH;

• Temperature;

• Incubation time;

• Mixing.

Compare total recovery and final concentration separately.

How to Prevent RNA Degradation

Use:

• RNase-free tubes and tips;

• Clean work areas;

• Suitable sample stabilization;

• Rapid lysis;

• Effective nuclease-denaturing reagents;

• Controlled processing time;

• Appropriate storage.

Avoid:

• Repeated freeze–thaw cycles;

• Unnecessary room-temperature delays;

• Contaminated water or buffers;

• Reusing open reagents without controls.

RNA degradation may appear as:

• Increased RT-qPCR Ct;

• Greater replicate variation;

• Poor sequencing quality;

• Loss of longer targets.

How to Prevent PCR and RT-PCR Inhibition

Potential inhibitors include:

• Ethanol;

• Chaotropic salts;

• Hemoglobin;

• Heparin;

• Mucus;

• Calcium compounds;

• Bile salts;

• Humic substances;

• Food-derived compounds.

Control strategies include:

• Appropriate sample pretreatment;

• Complete wash resuspension;

• Adequate wash volume;

• Controlled bead drying;

• Optimized elution;

• Internal amplification controls.

Do not evaluate purity only by A260/A280 or A260/A230.

Low-concentration viral samples may not produce reliable absorbance measurements.

Functional PCR or RT-PCR is often a more useful measure of usable recovery.

How to Use Internal Extraction Controls

An internal extraction control should help distinguish among:

• No viral target;

• Extraction failure;

• PCR inhibition;

• Instrument failure.

The control may be:

• A non-target RNA;

• A non-target DNA;

• A nonpathogenic particle or process control;

• An endogenous sample target.

During method development, evaluate:

• Addition stage;

• Control concentration;

• Extraction recovery;

• Competition with the viral target;

• Control Ct acceptance range.

The internal control should be tested across:

• Negative samples;

• Low-positive samples;

• High-positive samples;

• Different matrices;

• Different reagent lots.

How to Evaluate Viral RNA and DNA Extraction Performance

Recovery

Use a known viral nucleic acid, inactivated material or suitable process-control material.

Calculate recovery across:

• High concentration;

• Medium concentration;

• Low concentration;

• Concentrations near the intended detection limit.

PCR and RT-PCR performance

Compare:

• Ct values;

• Detection rate;

• Replicate consistency;

• Amplification efficiency;

• Internal-control Ct.

Precision

Evaluate:

• Within-run precision;

• Between-run precision;

• Operator variation;

• Instrument variation;

• Plate-position variation;

• Bead-lot variation.

Inhibition

Compare amplification of:

• Extracted samples;

• Diluted eluates;

• Spiked eluates;

• Clean controls.

Improved amplification after dilution may indicate inhibition.

Cross-contamination

Include:

• Negative extraction controls;

• Alternating high-positive and negative wells;

• Blank transport medium;

• No-template controls.

Bead carryover

Assess residual particles in the eluate and their effect on downstream amplification or optical measurements.

Common Problems and Troubleshooting

SANYU Silica Magnetic Beads for Viral Nucleic Acid Extraction

SANYU supplies silica magnetic beads through the Nanomicron Spheres product platform.

Its public product information lists applications that include viral DNA/RNA extraction and total RNA extraction. SANYU also offers a publicly listed 200 nm silica magnetic bead product for DNA and RNA purification applications.

Potential applications

SANYU silica magnetic beads may be evaluated for:

• Viral RNA extraction;

• Viral DNA extraction;

• Total viral nucleic acid extraction;

• Manual magnetic purification;

• Automated extraction instruments;

• Molecular diagnostic reagent development;

• Veterinary pathogen testing workflows;

• Research and sequencing sample preparation.

SANYU’s application materials also identify viral DNA/RNA extraction and multiplex viral nucleic acid extraction among the uses of its nucleic acid extraction magnetic microspheres.

What should be evaluated

Before approving SANYU or another raw-material supplier, test:

• Particle size and size distribution;

• Silica coating consistency;

• Magnetic collection time;

• Redispersibility;

• Sedimentation;

• Viral RNA recovery;

• Viral DNA recovery;

• Low-copy detection rate;

• Bead carryover;

• Buffer compatibility;

• Lot-to-lot variation.

Product-development positioning

SANYU silica magnetic beads should be treated as a functional raw material within a complete extraction system.

The final performance depends on:

• Sample pretreatment;

• Lysis chemistry;

• Binding buffer;

• Wash buffers;

• Carrier RNA;

• Magnet or extractor;

• Elution conditions.

A raw bead should not be presented as a complete validated viral extraction kit unless the full reagent system and intended use have undergone the required development and validation.

How to Choose a Silica Magnetic Bead Supplier

Evaluate suppliers in four areas.

Particle performance

Request:

• Mean particle diameter;

• D10, D50 and D90;

• CV or PDI;

• Solids concentration;

• Magnetic content;

• Magnetic response time;

• Sedimentation data;

• Redispersion data.

Viral extraction performance

Request or generate data for:

• Viral RNA recovery;

• Viral DNA recovery;

• Low-copy recovery;

• Internal-control recovery;

• RT-qPCR or qPCR performance;

• Bead carryover;

• Matrix compatibility.

Quality capability

Request:

• Certificate of Analysis;

• Safety Data Sheet;

• Product specification;

• Batch traceability;

• Stability information;

• Change-control policy.

Commercial capability

Confirm:

• Sample availability;

• Pilot quantity;

• Commercial production capacity;

• Lead time;

• Packaging;

• Reserved lots;

• Supply continuity.

Validation Requirements for IVD Kit Development

An IVD viral extraction kit requires application-specific validation.

Important areas include:

• Analytical sensitivity;

• Viral RNA recovery;

• Viral DNA recovery;

• Precision;

• Reproducibility;

• Interference;

• Cross-contamination;

• Sample stability;

• Reagent stability;

• Instrument compatibility;

• Matrix equivalency;

• Lot-to-lot consistency.

Analytical sensitivity

Test multiple replicates near the intended detection limit.

High-positive samples alone are not sufficient.

Interference

Evaluate potential interferents relevant to the sample, such as:

• Hemoglobin;

• Lipids;

• Mucus;

• Anticoagulants;

• Transport-medium additives;

• Food components;

• Common medications where relevant to the intended sample.

Inclusivity of extraction

The extraction system should be challenged with representative viral structures and genome types rather than assuming that one virus represents all viral targets.

Commercial lot qualification

Each bead lot should meet predefined requirements for:

• Particle size;

• Solids concentration;

• Magnetic response;

• Functional viral recovery;

• Carryover;

• Stability.

Information to Include in an RFQ

A viral extraction magnetic bead RFQ should include:

1. Target virus or virus category;

2. RNA, DNA or total nucleic acid extraction;

3. Sample type;

4. Sample input volume;

5. Transport medium;

6. Expected viral concentration range;

7. Required low-copy recovery;

8. Manual or automated workflow;

9. Extraction instrument;

10. Magnetic rod or liquid-handler format;

11. Tube, cartridge or plate type;

12. Samples per run;

13. Preferred particle size;

14. Required magnetic collection time;

15. Bead concentration;

16. Binding-buffer chemistry;

17. Wash-buffer chemistry;

18. Carrier RNA requirements;

19. Elution volume;

20. Downstream PCR, RT-PCR or sequencing method;

21. Minimum acceptable recovery;

22. Maximum acceptable Ct shift;

23. Maximum bead carryover;

24. Sample quantity;

25. Pilot order quantity;

26. Estimated annual demand;

27. Packaging requirements;

28. Required quality documents;

29. Shelf-life requirement;

30. OEM or private-label requirements.

Frequently Asked Questions

What magnetic beads are used for viral RNA extraction?

Silica or silica-like magnetic beads are commonly used because they reversibly bind RNA under suitable high-salt and alcohol-containing conditions.

Can the same beads extract viral DNA and RNA?

Yes, silica magnetic beads can recover both. The lysis, binding and quality-control conditions must be validated for each target type.

Why are silica magnetic beads suitable for low viral loads?

They can provide high accessible surface area, efficient solution-phase contact and small-volume elution. Actual low-copy recovery depends on the complete bead and buffer system.

Do silica beads recognize a specific virus?

No. Standard silica beads bind nucleic acids according to chemical conditions, not viral sequence.

Are viral RNA and DNA extracted together?

Total nucleic acid methods can extract both. RNA-only or DNA-only methods may use additional enzymes or selective chemistry.

What samples can be processed?

Potential samples include plasma, serum, blood, saliva, respiratory swabs, cell-culture supernatants, tissues, feces, milk, food and environmental samples. Each matrix requires separate validation.

Is carrier RNA always required?

No. It may improve low-copy recovery in some silica workflows, but it can interfere with certain quantification and sequencing applications.

Why is Proteinase K used?

It digests proteins, can reduce nuclease activity and may improve disruption of protein-rich viral particles or sample matrices.

Can magnetic beads inactivate viruses?

Magnetic beads themselves are not a validated virus-inactivation method. Inactivation depends on the lysis chemistry, contact conditions, virus and sample matrix.

Why is ethanol used in washing?

Ethanol helps maintain nucleic acid binding while salts and contaminants are removed.

Why does ethanol carryover affect RT-PCR?

Residual ethanol can inhibit reverse transcriptase and DNA polymerase activity.

Can viral extraction be automated?

Yes. Magnetic bead workflows can be automated on magnetic rod systems, liquid handlers, cartridge instruments and integrated molecular platforms.

Which is better for viral extraction: magnetic beads or spin columns?

Both can work. Magnetic beads are generally easier to automate and scale, while spin columns may be simpler for small manual batches.

How should viral extraction efficiency be measured?

Use suitable process controls and evaluate qPCR or RT-qPCR recovery, detection rate, Ct values, precision, inhibition and cross-contamination.

What causes low viral RNA recovery?

Common causes include RNA degradation, incomplete lysis, inadequate binding, poor bead mixing, bead loss and inefficient elution.

What causes false-negative PCR results after extraction?

Possible causes include low viral concentration, extraction failure, RNA degradation, PCR inhibitors or assay failure.

Does SANYU supply silica magnetic beads for viral extraction?

SANYU publicly lists silica magnetic beads for viral DNA/RNA and total RNA extraction applications. Compatibility with a specific sample, buffer system and instrument must be confirmed experimentally.

Conclusion

Silica magnetic beads provide a flexible solid phase for extracting viral RNA and DNA from clinical, veterinary, food and environmental samples.

Their main advantages include:

• Reversible nucleic acid binding;

• Magnetic separation without centrifugation;

• Low-input recovery potential;

• Small-volume elution;

• Automation compatibility;

• High-throughput scalability.

The standard workflow consists of:

1. Sample preparation;

2. Viral lysis;

3. Internal-control addition;

4. Nucleic acid binding;

5. Magnetic separation;

6. Washing;

7. Controlled drying;

8. Elution.

Viral extraction performance depends on much more than the magnetic bead alone.

The complete system must address:

• Viral particle lysis;

• RNA stability;

• Low-copy binding;

• Sample viscosity;

• PCR inhibitors;

• Transport-medium compatibility;

• Bead carryover;

• Internal controls;

• Cross-contamination.

SANYU supplies silica magnetic beads that can be evaluated as raw materials for viral DNA/RNA extraction, total nucleic acid purification and automated molecular diagnostic reagent development.

The final material should be tested using the actual:

• Sample matrix;

• Viral RNA or DNA target;

• Lysis formulation;

• Binding buffer;

• Wash system;

• Magnetic separator;

• Extraction instrument;

• Downstream PCR, RT-PCR or sequencing assay.

A structured validation program covering low-copy recovery, inhibition, precision, cross-contamination, stability and bead-lot consistency provides the most reliable route from silica magnetic bead screening to a commercially scalable viral nucleic acid extraction system.